ValuEngine cut shares of Oramed Pharmaceuticals (NASDAQ:ORMP) from a hold rating to a sell rating in a report published on Tuesday.
Several other equities research analysts also recently weighed in on the company. B. Riley downgraded Oramed Pharmaceuticals from a buy rating to a neutral rating in a research report on Monday, July 16th. HC Wainwright set a $25.00 target price on Oramed Pharmaceuticals and gave the stock a buy rating in a research report on Wednesday, June 6th.
ORMP stock opened at $4.98 on Tuesday. Oramed Pharmaceuticals has a 12-month low of $4.60 and a 12-month high of $11.34. The stock has a market cap of $88.90 million, a price-to-earnings ratio of -6.30 and a beta of 0.35.
Oramed Pharmaceuticals (NASDAQ:ORMP) last posted its quarterly earnings results on Thursday, July 12th. The biotechnology company reported ($0.30) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.27) by ($0.03). Oramed Pharmaceuticals had a negative net margin of 204.00% and a negative return on equity of 63.20%. The firm had revenue of $0.62 million for the quarter, compared to analysts’ expectations of $0.61 million. equities research analysts forecast that Oramed Pharmaceuticals will post -0.96 EPS for the current year.
A hedge fund recently bought a new stake in Oramed Pharmaceuticals stock. Millennium Management LLC bought a new position in Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 15,849 shares of the biotechnology company’s stock, valued at approximately $143,000. Millennium Management LLC owned 0.11% of Oramed Pharmaceuticals at the end of the most recent reporting period. Institutional investors own 1.52% of the company’s stock.
About Oramed Pharmaceuticals
Oramed Pharmaceuticals Inc engages in the research and development of pharmaceutical solutions for the use of orally ingestible capsules or pills for delivery of polypeptides. Its product portfolio includes ORMD-0801, an oral insulin capsule, which has completed Phase IIb clinical trials for the treatment of diabetes; and ORMD-0901, an analog for GLP-1 gastrointestinal hormone, which has completed Phase Ib clinical trials for the treatment of type 2 diabetes.
Featured Story: Outstanding Shares and The Effect on Share Price
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Oramed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oramed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.